Status:
COMPLETED
Study of the Safety and Immunogenicity of NasoVAX Extension
Lead Sponsor:
Altimmune, Inc.
Conditions:
Influenza
Eligibility:
All Genders
18-50 years
Brief Summary
This study is an extension to Study ALT-103-201, a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of...
Detailed Description
This study is an extension to Study ALT-103-201 to evaluate immunogenicity of NasoVAX administered by intranasal spray at a single dose of 1×1011 vp at Day 366 (± 60 days). Up to 15 subjects who recei...
Eligibility Criteria
Inclusion
- Inclusion:
- Receipt of NasoVAX at the 1×10(11th) vp dose in Study ALT-103-201
- Adequate venous access for phlebotomy
- Provision of written informed consent
- Exclusion:
- 1\. Any medical, psychiatric, or social condition or occupational or other responsibility that in the judgment of the Investigator would interfere with the subject providing an adequate blood sample or the subject's ability to give informed consent
Exclusion
Key Trial Info
Start Date :
January 21 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 18 2019
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT03760549
Start Date
January 21 2019
End Date
February 18 2019
Last Update
June 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Optimal Health Research
Rockville, Maryland, United States, 20850